Health
Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month
Novo Nordisk today announced that Wegovy® (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic® are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. This introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy® or Ozempic®. After those two months, patients will move to the new standard monthly self-pay price which Novo Nordisk is lowering from $499 to $349 p
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy® and Ozempic® for only $199 each beginning November 17, 2025","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Also effective November 17, Novo Nordisk is lowering the price of Wegovy® and Ozempic® for existing self-pay patients in the US from $499 to $349 per month*","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Self-pay pricing available through 70,000+ pharmacies nationwide, home delivery, and select telehealth providers","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"These offers build on Novo Nordisk's ongoing efforts to expand access to FDA-approved semaglutide medicines across the many different channels patients use to get their prescriptions","length":186,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":615,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., Nov. 17, 2025 /PRNewswire/ -- Novo Nordisk today announced that Wegovy® (semaglutide) injection 0.25 mg and 0.5 mg and Ozempic® are now available at a limited time price of $199 per month to new self-pay patients between now and March 31, 2026. This introductory offer is good for the first two months of therapy and applies to the two lowest doses (0.25 mg and 0.5 mg) of Wegovy® or Ozempic®. After those two months, patients will move to the new standard monthly self-pay price which Novo Nordisk is lowering from $499 to $349 per month*, also beginning today. These offers follow the recent agreement with the US Administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026 – and today, Novo Nordisk is bringing these prices to consumers months in advance of that commitment.","length":940,"tagName":"p"},{"type":"text","content":""As pioneers of the GLP-1 class, we are committed to ensuring that real, FDA-approved Wegovy® and Ozempic® are affordable and accessible to those who need them," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "The US healthcare system is complex, with different types of insurance and various ways for patients to obtain their medicines. Our new savings o...